Recently Featured

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

July 24, 2026
Ipsen has announced its intention to acquire Swiss biotech firm Memo Therapeutics in a deal potentially valued at $800 million. This acquisition is particularly significant as it provides Ipsen with access to an experimental medicine currently in late-stage testing, targeting a virus that frequently complicates the treatment of kidney transplant patients. The context of this…

AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project

July 24, 2026
QuantumCell has secured global rights to the NeuroRestore platform through a collaboration agreement with AlzeCure, a deal valued at over USD 2.2 billion. This partnership marks a significant milestone in the development of innovative therapies aimed at addressing neurodegenerative diseases, an area of increasing focus within the pharmaceutical industry. The NeuroRestore platform is designed to…

BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’

July 23, 2026
BridgeBio has successfully secured up to $1 billion in equity financing, a significant boost as the California-based biotech prepares to launch three new medicines, including its anticipated blockbuster, Attruby, for ATTR-CM. This substantial investment comes from notable financial partners, Sixth Street and HealthCare Royalty, underscoring the confidence in BridgeBio’s innovative pipeline and growth potential. The…

FDA Sets Decision Date for Sarepta’s DMD Drugs

July 23, 2026
The FDA has officially set a decision date for Sarepta Therapeutics’ drugs targeting Duchenne muscular dystrophy (DMD), a critical milestone for the company and the broader DMD community. This decision is particularly significant as it comes amidst increasing scrutiny of gene therapy products and their regulatory pathways, which have been under the spotlight following recent…

Ongoing Cases